GENE - CHEMICAL INTERACTIONS REPORT
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
Object Symbol | Qualifier | Evidence | With | Reference | Source | Notes | Original Reference(s) | Gsk3b | decreases activity | ISO | Gsk3b (Rattus norvegicus) | 6480464 | CTD | N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea results in decreased activity of GSK3B protein | PMID:16202587 | Gsk3b | multiple interactions | ISO | GSK3B (Homo sapiens) | 6480464 | CTD | [N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea results in decreased activity of GSK3B protein] inhibits the reaction [Okadaic Acid results in increased phosphorylation of MAPT protein]; [N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea results in decreased activity of GSK3B protein] results in increased susceptibility to [Troglitazone results in decreased expression of CCNB1 protein]; [N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea results in decreased activity of GSK3B protein] results in increased susceptibility to [Troglitazone results in decreased expression of CCND1 protein]; [N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea results in decreased activity of GSK3B protein] results in increased susceptibility to [Troglitazone results in decreased expression of CCNE1 protein]; [N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea results in decreased activity of GSK3B protein] results in increased susceptibility to [Troglitazone results in decreased expression of CDK2 protein]; [N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea results in decreased activity of GSK3B protein] results in increased susceptibility to [Troglitazone results in decreased expression of CDK4 protein]; [N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea results in decreased activity of GSK3B protein] results in increased susceptibility to [Troglitazone results in increased expression of BAX protein]; [N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea results in decreased activity of GSK3B protein] results in increased susceptibility to [Troglitazone results in increased expression of CASP3 protein]; [N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea results in decreased activity of GSK3B protein] results in increased susceptibility to [Troglitazone results in increased expression of CASP9 protein]; [N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea results in decreased activity of GSK3B protein] which results in decreased susceptibility to Okadaic Acid; [N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea results in decreased activity of GSK3B protein] which results in decreased susceptibility to Proadifen; [N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea results in decreased activity of GSK3B protein] which results in increased susceptibility to Troglitazone; N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea inhibits the reaction [Arsenic Trioxide results in decreased phosphorylation of GSK3B protein]; N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea inhibits the reaction [Okadaic Acid results in increased expression of GSK3B protein modified form]; N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea inhibits the reaction [Okadaic Acid results in increased expression of GSK3B protein] | PMID:20540935 PMID:21715663 PMID:22683934 PMID:32305283 | | ||||||||||||||||||||||
| Go Back to source page | Continue to Ontology report |